Expanded EU Approval for AbbVie's VENCLYXTO Boosts CLL Treatment Options
ABBV sits 21% above its 52-week low of $181.73.
Summary
AbbVie secured European Commission authorization for an expanded label for its oncology drug VENCLYXTO (venetoclax). This approval allows for new combinations with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia (CLL) patients. This significantly broadens the market for VENCLYXTO in the EU, offering fixed-duration, chemotherapy-free oral treatment options. The expanded label is a positive development for AbbVie's oncology portfolio, following recent positive news like the FDA approval of DECNUPAZ just two days prior.
At the time of this announcement, ABBV was trading at $219.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $386.3B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.